What type of study is this?

This is a Human Clinical Trial study (also classified as: In Vitro Study).

December 8, 2025Blood

LSD1 inhibition enhances venetoclax efficacy in Acute Myeloid Leukemia via metabolic rewiring

View Full Paper

Ask AI

Bookmark

Authors

Inhibition of LSD1 increases apoptosis in leukemic stem cell metabolism, suggesting new treatments for AML.

Co-treatment with venetoclax and bomedemstat significantly enhances apoptosis in acute myeloid leukemia models.
Synergistic effects were observed in 19 of 26 primary AML samples tested, indicating broad efficacy.
Analysis using bulk RNA sequencing revealed alterations in metabolism and increased leukemic differentiation.
These findings highlight the potential for novel therapeutic strategies targeting AML metabolism and signaling pathways.

Hartung et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Inhibition of LSD1 increases apoptosis in leukemic stem cell metabolism, suggesting new treatments for AML.

Co-treatment with venetoclax and bomedemstat significantly enhances apoptosis in acute myeloid leukemia models.
Synergistic effects were observed in 19 of 26 primary AML samples tested, indicating broad efficacy.
Analysis using bulk RNA sequencing revealed alterations in metabolism and increased leukemic differentiation.
These findings highlight the potential for novel therapeutic strategies targeting AML metabolism and signaling pathways.

Hartung et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark